Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Zinc probably leads to lower progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (moderate certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
Zinc probably leads to lower progression to neovascular AMD compared with placebo (moderate certainty).
1 finding from 1 review
Progression to geographic atrophy · people with AMD
Zinc showed no clear difference in progression to geographic atrophy compared with placebo (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Zinc showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · people with AMD
1 finding from 1 review
no estimate extracted
286 participants
Very low
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to geographic atrophy · people with AMD
Antioxidant multivitamin and mineral supplement showed no clear difference in progression to geographic atrophy compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Antioxidant multivitamin and mineral supplement probably leads to lower progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life · people with AMD
1 finding from 1 review
Adverse effects · people with AMD
Antioxidant multivitamin and mineral supplement may leads to lower adverse effects compared with placebo or no treatment (low certainty).
1 finding from 1 review
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to late AMD (neovascular AMD, geographic atrophy, or both) compared with placebo (low certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to neovascular AMD compared with placebo (low certainty).
1 finding from 1 review
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
1 finding from 1 review
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
Secondary hemorrhage at any time point · people with traumatic hyphema
Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: systemic hypotension · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found